Rubric Capital Management (New York)’s ARS Pharmaceuticals SPRY Stock Holding History

Rubric Capital Management (New York)’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$68.4M	Buy	8,540,861 +540,861	+7%	+$4.65M	0.63%	46
2026 Q1	$64.2M	Buy	8,000,000 +1,800,000	+29%	+$17.3M	0.68%	31
2025 Q4	$72.2M	Buy	6,200,000 +1,700,000	+38%	+$16.5M	0.86%	30
2025 Q3	$45.2M	Buy	4,500,000 +3,205,122	+248%	+$46M	0.51%	42
2025 Q2	$22.6M	Buy	1,294,878 +265,777	+26%	+$3.83M	0.34%	49
2025 Q1	$12.9M	Buy	+1,029,101	New	+$12.4M	0.23%	49
2024 Q3	–	Sell	-639,203	Closed	-$5.44M	–	74
2024 Q2	$5.44M	Hold	639,203	–	–	0.14%	60
2024 Q1	$6.53M	Hold	639,203	–	–	0.19%	60
2023 Q4	$3.5M	Hold	639,203	–	–	0.07%	54
2023 Q3	$2.42M	Sell	639,203 -2,160,000	-77%	-$14.2M	0.09%	60
2023 Q2	$18.8M	Sell	2,799,203 -681,509	-20%	-$4.55M	0.8%	37
2023 Q1	$22.7M	Buy	3,480,712 +490,148	+16%	+$3.77M	0.59%	40
2022 Q4	$25.5M	Buy	2,990,564 +295,394	+11%	+$1.92M	1.11%	30
2022 Q3	$14.2M	Buy	2,695,170 +1,708,717	+173%	+$8.42M	0.72%	38
2022 Q2	$4.18M	Buy	+986,453	New	+$3.44M	0.22%	67

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rubric Capital Management (New York)'s SPRY Position: Q2 2026 in Review

Rubric Capital Management (New York) increased its ARS Pharmaceuticals (SPRY) stake by 6.8% in Q2 2026, buying an estimated $4.65M and bringing the position to 8,540,861 shares worth $68.4M. The position accounts for 0.63% of the portfolio, ranked #46.

Rubric Capital Management (New York) first reported a position in SPRY in Q2 2022 and has held it in 15 quarters since. The position peaked at $72.2M in Q4 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Rubric Capital Management (New York) held 8,540,861 shares of ARS Pharmaceuticals worth $68.4M as of Q2 2026.
Rubric Capital Management (New York) bought 540,861 ARS Pharmaceuticals shares in Q2 2026, an estimated $4.65M.
ARS Pharmaceuticals made up 0.63% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #46 holding.
Rubric Capital Management (New York) first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
Rubric Capital Management (New York)'s ARS Pharmaceuticals position peaked at $72.2M in Q4 2025.
206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.